Science News

... from universities, journals, and other research organizations

Combination Therapy In HIV+ Children

ScienceDaily (June 6, 1997) — A combination therapy of stavudine (d4T), didanosine (ddI) and indinavir was well-tolerated in a study of HIV-infected children.

The study, conducted by Dr. Mark Kline, associate professor of pediatrics at Baylor College of Medicine in Houston, demonstrated that the drug combination was safe in a small group of symptomatic children.

"No child required either a dose reduction or interruption of therapy," said Kline. "In addition, there were marked changes in CD4 lymphocyte counts and blood HIV RNA concentrations, which suggests that there is potent antiviral activity."

The study evaluated the pharmacokinetics, tolerance, safety, immunologic effects, and antiviral activity of the combination therapy in 12 children, ages 4 to 13.

The children were assessed every four weeks for a period of 24 weeks.

All of the children had been treated previously with nucleoside antiretroviral agents including AZT, ddI and/or d4T.

"There was no obvious adverse interaction between d4T, ddI and indinavir when given in combination," Kline said. "Combination therapy produced impressive decreases in virus load in the body, and CD4 lymphocyte counts increased dramatically, suggesting improvement in the health of the patients' immune systems."

In addition, Kline found substantial amounts of indinavir in cerebrospinal fluid and an absence of HIV RNA, indicating there were antiviral effects within the central nervous system. Many HIV-infected children experience neurologic and developmental problems as a result of HIV's effects on the central nervous system. The research was presented last month at the the annual meeting of the Pediatric Academic Societies in Washington, DC.

Recommend this story on Facebook, Twitter,
and Google +1:

Other bookmarking and sharing tools:

| More

Story Source:

The above story is reprinted from materials provided by Johns Hopkins Children's Center.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.


APA

MLA

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Search ScienceDaily

Number of stories in archives: 114,600

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily's archives for related news topics,
the latest news stories, reference articles, science videos, images, and books.

 
  more breaking science news

Social Networks


Recommend this story on Facebook, Twitter,
and Google +1:
Other bookmarking and sharing tools:
| More

Breaking News

... from NewsDaily.com

In Other News ...

Copyright Reuters 2008. See Restrictions.

Free Subscriptions

... from ScienceDaily

Get the latest science news with our free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Feedback

... we want to hear from you!

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?

 
Post this page to your favorite social bookmarking site:
close
Include this item in your blog or web site:
close
Cite this article in your essay, paper, or report:
close
Email this page's link to a friend or colleague:
close